Document is current
Any future updates will be listed below
-
Authors
Zhuang, Zhe https://orcid.org/0000-0001-6679-0496
Byun, Woong Sub https://orcid.org/0000-0003-4676-3698
Chrustowicz, Jakub https://orcid.org/0000-0002-3059-1863
Kozicka, Zuzanna
Li, Veronica L.
Abeja, Dinah M.
Donovan, Katherine A. https://orcid.org/0000-0002-8539-5106
Sepic, Sara
You, Inchul
Słabicki, Mikołaj https://orcid.org/0000-0001-6317-9296
Fischer, Eric S. https://orcid.org/0000-0001-7337-6306
Hinshaw, Stephen M. https://orcid.org/0000-0003-4215-5206
Ebert, Benjamin L. https://orcid.org/0000-0003-0197-5451
Schulman, Brenda A. https://orcid.org/0000-0002-3083-1126
Gray, Nathanael S. https://orcid.org/0000-0001-5354-7403
- License Information
-
More Information
Article History
Received: 13 December 2025
Accepted: 4 March 2026
First Online: 6 April 2026
Competing interests
: N.S.G. is a founder, science advisory board member (SAB) and equity holder in Syros, C4, Allorion, Lighthorse, Voronoi, Inception, Matchpoint, Versant, Redtree, Shenandoah (board member), Larkspur (board member) and Soltego (board member). The N.S.G. lab receives or has received research funding from Novartis, Takeda, Astellas, Taiho, Jansen, Kinogen, Arbella, Deerfield, Springworks, Interline and Sanofi. B.A.S. is a member of the scientific advisory board of Proxygen and coinventor of intellectual property licensed to Cinsano. B.L.E. has received research funding from Novartis and Calico, has received consulting fees from Abbvie and is an SAB member and shareholder for Neomorph, Big Sur Bio, Skyhawk Therapeutics and Exo Therapeutics. E.S.F. is a founder, SAB member and equity holder of Civetta Therapeutics, Proximity Therapeutics, Anvia Therapeutics (also board of directors), Nias Bio, Stelexis Biosciences and Neomorph (also board of directors), an equity holder and SAB member for Photys Therapeutics and Ajax Therapeutics and an equity holder in Lighthorse Therapeutics and Avilar. E.S.F. is also a consultant to Novartis, EcoR1 capital, Odyssey and Deerfield. The E.S.F. lab receives or has received research funding from Deerfield, Novartis, Ajax, Interline, Bayer and Astellas. K.A.D. receives or has received consulting fees from Kronos Bio and Neomorph. M.S. has received research funding from Calico Life Sciences. All other authors declare no competing interests.
